Skip to content

US · REPL · BIOTECHNOLOGY

Replimune Group, Inc. (REPL) intrinsic value and stock valuation

$19.07as of 2026-11-21 · Mkt cap 993.07M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Replimune Group, Inc. DCF and intrinsic value

InvestorsCraft values REPL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from REPL’s statements →

Replimune Group, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Woburn, MA 01801 replimune.com

How the business is doing

Fiscal 2017–2026, USD

Revenue
$0.00
20172026
Net income
-$-313.94M
20172026
Free cash flow
-$-284.57M
20172026
Total equity
$166.2M-19.7% 5y CAGRd
20172026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-319.92M-$-261.63M-$-234.77M-$-177.08M-$-121.48M
Net income-$-313.94M-$-247.3M-$-215.79M-$-174.28M-$-118.04M
EPSd-$-3.38M-$-3.07M-$-3.24M-$-2.99M-$-2.26M
Operating cash flow-$-280.34M-$-192.25M-$-185.47M-$-128.05M-$-82.18M
Capital expenditure-$-4.22M-$-6.69M-$-5.66M-$-2.27M-$-2.34M
Free cash flow-$-284.57M-$-198.94M-$-191.13M-$-130.32M-$-84.52M
Total assets$332.4M$551.3M$487.7M$646.6M$461.2M
Total debt$111.6M$76.2M$75.9M$60.8M$32.8M
Net debt-$-97.44M-$-34.95M$1.41M-$-85.83M-$-73.11M
Total equity$166.2M$415.8M$374.5M$555.3M$411.2M
Cash and short-term investments$268.9M$483.8M$420.7M$583.4M$395.7M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$4.58M
Gross profit$0.00$0.00$0.00$0.00-$-4.58M
Research and development expenses$221.2M$189.5M$175M$126.5M$80.6M
Selling, general and administrative expenses$98.7M$0.00$0.00$0.00$36.3M
Other expenses$0.00$72.2M$59.8M$50.6M$0.00
Operating expenses$319.9M$261.6M$234.8M$177.1M$116.9M
Cost and expenses$319.9M$261.6M$234.8M$177.1M$121.5M
Interest income$13.6M$21.1M$23.4M$10M$390K
Interest expense$8.86M$7.89M$6.66M$4.16M$2.22M
Depreciation and amortization$3.33M$5.93M$5.08M$2.45M$4.58M
Ebitda-$-302.3M-$-253.92M-$-227.77M-$-171.72M-$-114.41M
Operating income-$-319.92M-$-261.63M-$-234.77M-$-177.08M-$-121.48M
Total other income/expenses, net$5.43M$14.8M$19.4M$3.08M$280K
Income before tax-$-314.49M-$-246.83M-$-215.39M-$-174M-$-121.21M
Income tax expense-$-550K$470K$410K$290K-$-3.17M
Net income-$-313.94M-$-247.3M-$-215.79M-$-174.28M-$-118.04M
Weighted average shares outstanding$92.8M$80.6M$66.6M$58.2M$52.2M
Weighted average diluted shares outstanding$92.8M$80.6M$66.6M$58.2M$52.2M
Balance sheet
20262025202420232022
Cash and short-term investments$268.9M$483.8M$420.7M$583.4M$395.7M
Net receivables$1.62M$3.73M$4.92M$2.94M$3.06M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$279.1M$495.9M$433.7M$592.6M$404M
Property, plant and equipment, net$48.6M$52.6M$52.4M$52.4M$55.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$53.3M$55.5M$54.1M$54M$57.2M
Total assets$332.4M$551.3M$487.7M$646.6M$461.2M
Accounts payable$6.67M$12.5M$2.58M$5.36M$3.73M
Short-term debt$4.04M$3.98M$3.88M$3.76M$3.63M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$58.2M$62.4M$40.4M$33.8M$20.8M
Long-term debt$107.6M$72.2M$72M$57M$29.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$108M$73.1M$72.8M$57.5M$29.2M
Capital lease obligations$24.2M$29.8M$31.1M$32.1M$32.8M
Total liabilities$166.2M$135.5M$113.2M$91.3M$50M
Common stock$80K$80K$60K$60K$50K
Retained earnings-$-1.26B-$-948.58M-$-701.28M-$-485.49M-$-311.2M
Accumulated other comprehensive income (loss)$5.4M$5.45M$4.86M$5.73M-$-970K
Total equity$166.2M$415.8M$374.5M$555.3M$411.2M
Total investments$59.9M$372.7M$346.2M$436.8M$289.7M
Total debt$111.6M$76.2M$75.9M$60.8M$32.8M
Net debt-$-97.44M-$-34.95M$1.41M-$-85.83M-$-73.11M
Cash flow statement
20262025202420232022
Net income-$-313.94M-$-247.3M-$-215.79M-$-174.28M-$-118.04M
Depreciation and amortization$4.1M$3.5M$2.65M$2.45M$2.15M
Stock-based compensation$32.3M$35M$34.1M$28.1M$24.3M
Change in working capital-$-3.84M$24.1M$5.48M$15.1M$7.24M
Accounts receivable$450K$1.3M-$-1.92M-$-60K-$-250K
Inventory$0.00$0.00$0.00$60K$250K
Accounts payable-$-4.94M$9.94M-$-2.79M$1.98M$1.12M
Net cash provided by operating activities-$-280.34M-$-192.25M-$-185.47M-$-128.05M-$-82.18M
Investments in property, plant and equipment-$-4.22M-$-6.69M-$-5.66M-$-2.27M-$-2.34M
Acquisitions, net$0.00$0.00$0.00$140K-$0.00
Net cash used for investing activities$310.8M-$-23.8M$97.2M-$-142.5M-$-1.81M
Common stock issued$32M$155.7M$1.76M$187.3M$6.86M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$66.3M$252.4M$16.3M$311.3M$6.6M
Net change in cash$97.9M$36.7M-$-72.07M$40.6M-$-76.57M
Cash at end of period$210.7M$112.8M$76.2M$148.2M$107.6M
Operating cash flow-$-280.34M-$-192.25M-$-185.47M-$-128.05M-$-82.18M
Capital expenditure-$-4.22M-$-6.69M-$-5.66M-$-2.27M-$-2.34M
Free cash flow-$-284.57M-$-198.94M-$-191.13M-$-130.32M-$-84.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Replimune Group, Inc.

        Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

        CEO
        Sushil Patel
        Employees
        465
        Beta
        0.87

        Explore

        Frequently asked questions

        What is the intrinsic value of Replimune Group, Inc. (REPL)?

        InvestorsCraft does not currently publish an intrinsic value for REPL. How the IC value is calculated.

        Is REPL undervalued?

        InvestorsCraft does not publish an undervaluation signal for REPL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.